{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:11:15Z","timestamp":1783645875846,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Drug combinations may have a crucial role in treating infections due to multidrug resistant <jats:italic>Acinetobacter spp<\/jats:italic>. One suggested combination is colistin with teicoplanin. The effect of colistin on <jats:italic>Acinetobacter spp<\/jats:italic>. outer membrane can permit teicoplanin to its target in the cell wall. The aim of this study was to evaluate the synergistic activity of colistin and teicoplanin combination against 29 multidrug resistant isolates of <jats:italic>Acinetobacter spp<\/jats:italic>. The antimicrobial activity of colistin alone and in combination with teicoplanin was assessed using MIC and time\u2013kill assays. The combination of 1\u2009mg\/l colistin and 10\u2009mg\/l teicoplanin showed in vitro synergism against all tested <jats:italic>Acinetobacter i<\/jats:italic>solates except one (<jats:italic>Acinetobacter lowffii<\/jats:italic>). The combination of 1\u2009mg\/l colistin and 10\u2009mg\/l teicoplanin was bactericidal at 6\u2009h against 100% of <jats:italic>Acinetobacter baumannii<\/jats:italic> isolates with no bacterial regrowth at 24\u2009h. The same combination was bactericidal against three out of seven non-baumannii <jats:italic>Acinetobacter<\/jats:italic> isolates. The increased concentration of teicoplanin (20\u2009mg\/l) was synergistic but still not bactericidal against the four remaining isolates. The combination of colistin and teicoplanin was synergistic against all tested <jats:italic>Acinetobacter spp<\/jats:italic> It is therefore recommended that clinical trials are conducted to clarify the therapeutic potential of the combination.<\/jats:p>","DOI":"10.1038\/s41429-022-00509-7","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T09:02:46Z","timestamp":1643360566000},"page":"181-184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["In vitro synergistic activity of colistin and teicoplanin combination against multidrug-resistant Acinetobacter spp"],"prefix":"10.1038","volume":"75","author":[{"given":"Osama Mohamed Samy Mohamed","family":"Rady","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"El-Attar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8260-0111","authenticated-orcid":false,"given":"Amira","family":"Amine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"key":"509_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jhin.2019.09.021","volume":"104","author":"P Nasr","year":"2020","unstructured":"Nasr P. Genetics, epidemiology, and clinical manifestations of multidrug-resistant Acinetobacter baumannii. J Hosp Infect. 2020;104:4\u201311.","journal-title":"J Hosp Infect"},{"key":"509_CR2","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s12275-017-7288-4","volume":"55","author":"B Shin","year":"2017","unstructured":"Shin B, Park W. Antibiotic resistance of pathogenic Acinetobacter species and emerging combination therapy. J Microbiol. 2017;55:837\u201349.","journal-title":"J Microbiol"},{"key":"509_CR3","doi-asserted-by":"publisher","first-page":"106065","DOI":"10.1016\/j.ijantimicag.2020.106065","volume":"56","author":"S Karakonstantis","year":"2020","unstructured":"Karakonstantis S, Saridakis I. Colistin heteroresistance in Acinetobacter spp.: systematic review and meta-analysis of the prevalence and discussion of the mechanisms and potential therapeutic implications. Int J Antimicrob Agents. 2020;56:106065.","journal-title":"Int J Antimicrob Agents"},{"key":"509_CR4","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/jac\/dkr069","volume":"66","author":"DW Wareham","year":"2011","unstructured":"Wareham DW, Gordon NC, Hornsey M. In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother. 2011;66:1047\u201351.","journal-title":"J Antimicrob Chemother"},{"key":"509_CR5","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 29th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2019."},{"key":"509_CR6","doi-asserted-by":"publisher","first-page":"e01523","DOI":"10.1128\/JCM.01523-17","volume":"56","author":"E Carretto","year":"2018","unstructured":"Carretto E, Brovarone F, Russello G, Nardini P, El-Bouseary MM, Aboklaish AF, et al. Clinical validation of SensiTest colistin, a broth microdilution-based method to evaluate colistin MICs. J Clin Microbiol. 2018;56:e01523\u201317.","journal-title":"J Clin Microbiol"},{"key":"509_CR7","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Methods for determining bactericidal activity of antimicrobial agents: approved guideline M26-A. Wayne, PA: Clinical and Laboratory Standards Institute; 1999."},{"key":"509_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1055\/s-0034-1398390","volume":"36","author":"CB Landersdorfer","year":"2015","unstructured":"Landersdorfer CB, Nation RL. Colistin: how should it be dosed for the critically ill? Semin Respir Crit Care Med. 2015;36:126\u201335.","journal-title":"Semin Respir Crit Care Med"},{"key":"509_CR9","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ijantimicag.2008.05.012","volume":"32","author":"AJ Brink","year":"2008","unstructured":"Brink AJ, Richards GA, Cummins RR, Lambson J. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis. Int J Antimicrob Agents. 2008;32:455\u20138.","journal-title":"Int J Antimicrob Agents"},{"key":"509_CR10","doi-asserted-by":"publisher","first-page":"6774","DOI":"10.1128\/AAC.00839-16","volume":"60","author":"S Bae","year":"2016","unstructured":"Bae S, Kim MC, Park SJ, Kim HS, Sung H, Kim MN, et al. In vitro synergistic activity of antimicrobial agents in combination against clinical isolates of colistin-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60:6774\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"509_CR11","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1128\/AAC.49.7.2959-2964.2005","volume":"49","author":"GA Pankey","year":"2005","unstructured":"Pankey GA, Ashcraft DS. In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005;49:2959\u201364.","journal-title":"Antimicrob Agents Chemother"},{"key":"509_CR12","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/jac\/dkl512","volume":"59","author":"RJ Owen","year":"2007","unstructured":"Owen RJ, Li J, Nation RL, Spelman D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother. 2007;59:473\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"509_CR13","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2217\/fmb-2019-0022","volume":"14","author":"D Sanderink","year":"2019","unstructured":"Sanderink D, Cassisa V, Chenouard R, Mahieu R, Kempf M, Dub\u00e9e V, et al. Colistin-glycopeptide combinations against multidrug-resistant Acinetobacter baumannii in a mouse model of pneumonia. Future Microbiol. 2019;14:581\u20136.","journal-title":"Future Microbiol"},{"key":"509_CR14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jinf.2014.09.004","volume":"70","author":"MA Fitzpatrick","year":"2015","unstructured":"Fitzpatrick MA, Ozer E, Bolon MK, Hauser AR. Influence of ACB complex genospecies on clinical outcomes in a U.S. hospital with high rates of multidrug resistance. J Infect. 2015;70:144\u201352.","journal-title":"J Infect"},{"key":"509_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.jmii.2013.02.002","volume":"47","author":"L Huang","year":"2014","unstructured":"Huang L, Chen TL, Lee YT, Lee MH, Kuo SC, Yu KW, et al. Risk factors for imipenem-nonsusceptible Acinetobacter nosocomialis bloodstream infection. J Microbiol Immunol Infect. 2014;47:311\u20137.","journal-title":"J Microbiol Immunol Infect"},{"key":"509_CR16","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/jac\/dkr200","volume":"66","author":"YC Lee","year":"2011","unstructured":"Lee YC, Huang YT, Tan CK, Kuo YW, Liao CH, Lee PI, et al. Acinetobacter baumannii and Acinetobacter genospecies 13TU and 3 bacteraemia: comparison of clinical features, prognostic factors and outcomes. J Antimicrob Chemother. 2011;66:1839\u201346.","journal-title":"J Antimicrob Chemother"},{"key":"509_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-311","volume":"13","author":"YS Yang","year":"2013","unstructured":"Yang YS, Lee YT, Tsai WC, Kuo SC, Sun JR, Yang CH, et al. Comparison between bacteremia caused by carbapenem resistant Acinetobacter baumannii and Acinetobacter nosocomialis. BMC Infect Dis. 2013;13:311.","journal-title":"BMC Infect Dis"},{"key":"509_CR18","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/cid\/ciq154","volume":"52","author":"YC Chuang","year":"2011","unstructured":"Chuang YC, Sheng WH, Li SY, Lin YC, Wang JT, Chen YC, et al. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia. Clin Infect Dis. 2011;52:352\u201360.","journal-title":"Clin Infect Dis"},{"key":"509_CR19","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1128\/JCM.01798-07","volume":"46","author":"YC Lin","year":"2008","unstructured":"Lin YC, Sheng WH, Chang SC, Wang JT, Chen YC, Wu RJ, et al. Application of a microsphere-based array for rapid identification of Acinetobacter spp. with distinct antimicrobial susceptibilities. J Clin Microbiol. 2008;46:612\u20137.","journal-title":"J Clin Microbiol"},{"key":"509_CR20","doi-asserted-by":"publisher","first-page":"105956","DOI":"10.1016\/j.ijantimicag.2020.105956","volume":"55","author":"YT Lee","year":"2020","unstructured":"Lee YT, Sun JR, Wang YC, Chiu CH, Kuo SC, Chen TL, et al. Multicentre study of risk factors for mortality in patients with Acinetobacter bacteraemia receiving colistin treatment. Int J Antimicrob Agents. 2020;55:105956.","journal-title":"Int J Antimicrob Agents"}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41429-022-00509-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-022-00509-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-022-00509-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T16:27:51Z","timestamp":1643992071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41429-022-00509-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["509"],"URL":"https:\/\/doi.org\/10.1038\/s41429-022-00509-7","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]},"assertion":[{"value":"18 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}